CLL is second indication approved by FDA for ibrutinib; previously approved for mantle cell lymphoma patients
Louis J. DeGennaro, Ph.D., Named Interim President and CEO
The top national LLS partner helping to make Someday, Today, for blood cancer
If you're a member of the media, please direct all inquiries for The Leukemia & Lymphoma Society's (LLS's) Western & Central New York Chapter to email@example.com or call our Chapter Office at 716.834.2578 or 800.784.2368, ext. 4663.